| 212  | reviewed by a physician who is currently licensed as a physician and surgeon in a state, district,                  |
|------|---|
| 213  | or territory of the United States.  |
| 214  | (d) The appeal of an adverse determination requested by a physician regarding clinical                              |
| 215  | or medical necessity of a drug, may only be reviewed by an individual who is currently licensed                     |
| 216  | in a state, district, or territory of the United States as:   |
| 217  | (i) a physician and surgeon; or   |
| 218  | (ii) a pharmacist.  |
| 219  | (e) An insurer shall ensure that an adverse preauthorization determination regarding                                |
| 220  | clinical or medical necessity is made by an individual who:   |
| 221  | (i) has knowledge of the medical condition or disease of the enrollee for whom the                                  |
| 222  | authorization is requested; or  |
| 223  | (ii) consults with a specialist who has knowledge of the medical condition or disease of                            |
| 224  | the enrollee for whom the authorization is requested regarding the request before making the                        |
| 225  | determination.  |
| 226  | (f) An insurer shall specify how long an authorization is valid.  |
| 227  | (4) (a) An insurer that removes a drug from the insurer's formulary shall $\$ \rightarrow :$                        |
| 227a | (i) ←Ŝ permit an  |
| 228  | enrollee, an enrollee's designee, or an enrollee's network provider to request an exemption from                    |
| 229  | the change to the formulary for the purpose of providing the patient with continuity of care $\$ \rightarrow [:]$ : |
| 229a | <u>and</u>  |
| 229b | (ii) have a process to review and make a decision regarding an exemption requested under                            |
| 229c | Subsection $(4)(a)(i)$ . $\leftarrow \hat{S}$   |
| 230  | (b) If an insurer makes a change to the formulary for a drug in the middle of a plan                                |
| 231  | year, the insurer may not implement the changes for an enrollee that is on an active course of                      |
| 232  | treatment for the drug unless the insurer provides the enrollee with notice at least 30 days                        |
| 233  | before the day on which the change is implemented.  |
| 234  | (5) Before April 1, 2021, and before April 1 of each year thereafter, an insurer with a                             |
| 235  | preauthorization requirement shall report to the department, for the previous calendar year, the                    |
| 236  | percentage of authorizations, not including a claim involving urgent care as defined in 29                          |
| 237  | C.F.R. Sec. 2560.503-1, for which the insurer notified a provider regarding an authorization or                     |
| 238  | adverse preauthorization determination more than one week after the day on which the insurer                        |
| 239  | received the request for authorization.   |
| 240  | (6) An insurer may not have a preauthorization requirement for emergency health care                                |
| 241  | as described in Section 31A-22-627.   |
| 242  | Section 5. Effective date.  |